Lipid A Mimics with Aromatic Groups for Safer Vaccine Adjuvants
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine adjuvants, such as Alum, have limitations in immunogenicity and require co-administration with antigens, and traditional lipid A-based adjuvants are too toxic for human use, necessitating the development of safer and more effective immunostimulatory compounds.
Innovation Solution
Development of novel lipid A mimics that replace sugar residues with aromatic groups, potentially enhancing binding affinity to Toll-like receptor 4 (TLR4) and providing improved immunostimulatory activity while reducing toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional lipid A-based adjuvants are used to enhance immunostimulatory activity, then immunogenicity is improved, but toxicity increases making them unsuitable for human use
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of lipid A molecules through structural modifications such as reducing the number of acyl chains, changing fatty acid composition, or removing phosphate groups. These parameter changes maintain the immunostimulatory activity (binding to TLR4) while reducing the toxicity and pyrogenic effects, making the adjuvant suitable for human vaccination.
Solution Approach 2:
The patent applies local quality by making specific localized modifications to particular regions of the lipid A molecule rather than uniform changes. For example, modifying only the acyl chain length or composition at specific positions while preserving the core glucosamine disaccharide structure and other critical regions maintains TLR4 binding capability while reducing harmful effects in specific areas of the molecule.
2Object-affected harmful factors
If subunit vaccines are used to improve safety, then harmful factors are reduced, but immunogenicity deteriorates requiring adjuvant co-administration
Solution Approach 1:
The patent applies merging by combining the subunit vaccine antigen with the modified lipid A adjuvant in a single formulation. This integration allows the safe subunit vaccine to achieve sufficient immunogenicity through the immunostimulatory activity of the modified lipid A, which activates innate immunity via TLR4 and enhances adaptive immune responses to the antigen.
3Ease of manufacture
If Alum adjuvant is used to simplify vaccine formulation, then ease of manufacture is improved, but immunogenicity is insufficient requiring additional adjuvant components
Solution Approach 1:
The patent applies parameter changes by developing modified lipid A adjuvants with optimized chemical parameters that provide stronger and more versatile immunostimulatory activity compared to Alum. These modifications enable the adjuvant to work effectively with various types of antigens including subunit vaccines, and can induce both Th1 and Th2 immune responses depending on the specific modification, providing improved immunogenicity while maintaining formulation feasibility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The lipid A mimics demonstrate enhanced immunostimulatory activity, capable of inducing antibody and cell-mediated immune responses, and show promise in treating or preventing diseases by potentiating immune responses without the toxicity issues of natural lipid A.
Implementation Method 1
LPS/lipid A is recognized by Toll-like receptor 4 (TLR4), a member of TLR protein family, which is associated with another protein MD-2. The activation of the TLR4/MD-2 receptor complex leads to downstream signalling pathways that ultimately regulate innate immunity as well as the development of adaptive immune response.
Data Source
AI summary
The invention provides lipid A mimics in which one or both of the sugar residues of a natural lipid A disaccharide backbone has been replaced with an aromatic group. These lipid A mimics may further differ from a natural lipid A molecule with respect to other structural characteristics, such as, a different number of phosphate groups present, changes in the number, structure and location of lipid chains and/or changes in the spacing and linkage of the sugar residues (or their aromatic replacements). The lipid A mimics may be lipid A agonists and as such may be useful as immunostimulatory agents in inducing or patenting an antibody and/or cell-mediated immune response, or may be lipid A antagonists and as such may be useful in treating or preventing a lipopolysaccharide (LPS)/lipid A-mediated disease or disorder. Also provided are methods for preparing the lipid A mimics.